Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Phase: Phase 1"
topic_facet:"Medical Condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Primary+Myelofibrosis+%28PMF%29%2C+Post%E2%80%93Polycythemia+Vera+MF+%28Post%E2%80%93PV-MF%29%2C+Or+Post%E2%80%93Essential+Thrombocythemia+MF+%28Post-ET-MF%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074689Term%3A+Post+polycythemia+vera+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074690Term%3A+Post+essential+thrombocythemia+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.1Level%3A+LLTClassification+code+10074691Term%3A+Post+polycythaemia+vera+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074692Term%3A+Post+essential+thrombocythaemia+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+20.0Level%3A+PTClassification+code+10077161Term%3A+Primary+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Primary+Myelofibrosis+%28PMF%29%2C+Post%E2%80%93Polycythemia+Vera+MF+%28Post%E2%80%93PV-MF%29%2C+Or+Post%E2%80%93Essential+Thrombocythemia+MF+%28Post-ET-MF%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074689Term%3A+Post+polycythemia+vera+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074690Term%3A+Post+essential+thrombocythemia+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.1Level%3A+LLTClassification+code+10074691Term%3A+Post+polycythaemia+vera+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074692Term%3A+Post+essential+thrombocythaemia+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+20.0Level%3A+PTClassification+code+10077161Term%3A+Primary+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Primary+Myelofibrosis+%28PMF%29%2C+Post%E2%80%93Polycythemia+Vera+MF+%28Post%E2%80%93PV-MF%29%2C+Or+Post%E2%80%93Essential+Thrombocythemia+MF+%28Post-ET-MF%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074689Term%3A+Post+polycythemia+vera+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074690Term%3A+Post+essential+thrombocythemia+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.1Level%3A+LLTClassification+code+10074691Term%3A+Post+polycythaemia+vera+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10074692Term%3A+Post+essential+thrombocythaemia+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29+MedDRA+version%3A+20.0Level%3A+PTClassification+code+10077161Term%3A+Primary+myelofibrosisSystem+Organ+Class%3A+10029104+-+Neoplasms+benign%2C+malignant+and+unspecified+%28incl+cysts+and+polyps%29%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (12)
1
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
6
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
7
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib - KRT-232-109
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
10
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib : An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib - KRT-232-109
enthalten in:
WHO International Clinical Trials Registry Platform
| 2020
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Phase: Phase 1
Filter aufheben
Thema: Medical Condition: Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
12
Aufsätze
12
E-Artikel
12
E-Ressourcen
Zeitschriftentitel
12
WHO International Clinical Trials Registry Plat...
Thema
12
610
Medical Condition: Primary Myelofibrosis (PMF),...
Phase: Phase 1
12
Recruitment Status: Authorised-recruitment may ...
12
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2022
4
2021
4
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
12
Englisch
Haven't found what you're looking for?
Wird geladen...